SB, I believe that the company has already gone over and above what most early stage biotechs are willing to do with future guidance. They're doing very good relative to guidance, but it appears that the market continues to yawn. I believe they may have simply said "No reason to update guidance at this time as it doesn't change the company's trajectory toward success and we're confident in the guidance already given." It's not their job to prop up the share price per se, and they've already demonstrated to all of us as shareholders that they're delivering on their growth projections.
Patience is the challenge for most of us who were hopeful for that quick buyout option. If it's going to take longer to get to those higher share price numbers, so be it. IOVA will still likely prove to be one of my better if not best investments over the coming years. In this I'm very confident.
Good luck.
Market Data 
Markets 
AI
